Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

HUTCHMED (China) Limited - American Depositary Shares (NQ:HCM)

16.21 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 351
Open 16.21
Bid (Size) 15.68 (1)
Ask (Size) 15.90 (2)
Prev. Close 16.21
Today's Range 16.21 - 16.21
52wk Range 11.51 - 21.50
Shares Outstanding 871,256,270
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
HUTCHMED Completes Patient Enrollment of SANOVO Phase III Trial of ORPATHYS® and TAGRISSO® Combination as a First-Line Therapy for Certain Lung Cancer Patients in China
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED Reports 2025 Interim Results
From HUTCHMED (China) Limited
Via GlobeNewswire

Performance

YTD
+7.5%
+7.5%
1 Month
-8.6%
-8.6%
3 Month
+22.2%
+22.2%
6 Month
+18.1%
+18.1%
1 Year
-12.2%
-12.2%

More News

Read More
Earnings Scheduled For August 7, 2025
Via Benzinga
HUTCHMED to Announce 2025 Half-Year Financial Results
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED Announces China Approval for ORPATHYS® in Combination with TAGRISSO® for the Treatment of Lung Cancer Patients with MET Amplification After Progression on First-Line EGFR Inhibitor Therapy
From HUTCHMED (China) Limited
Via GlobeNewswire
Hutchmed Stock Hits Over One-Month High After China Accepts Kidney Cancer NDA Filed With Partner Innovent Biologics
Via Stocktwits
HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Renal Cell Carcinoma
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED Highlights SACHI Phase III Study Data Presented at the 2025 ASCO Annual Meeting
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED Highlights Clinical Data to be Presented at the 2025 ASCO Annual Meeting
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2025
From HUTCHMED (China) Limited
Via GlobeNewswire
Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing
From Virtual Investor Conferences
Via GlobeNewswire
HUTCHMED Completes Patient Enrollment of a Phase II Registration Study of Savolitinib in Gastric Cancer in China
From HUTCHMED (China) Limited
Via GlobeNewswire
UPDATE - International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on May 15, 2025
From Virtual Investor Conferences
Via GlobeNewswire
Progress Software Posts Upbeat Results, Joins Microvast, PVH And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on May 15, 2025
From Virtual Investor Conferences
Via GlobeNewswire
HUTCHMED Announces NMPA Conditional Approval for TAZVERIK® (tazemetostat) for the Treatment of Relapsed or Refractory Follicular Lymphoma
From HUTCHMED (China) Limited
Via GlobeNewswire
Intended Retirement of Independent Non-executive Directors and changes of composition of board committees
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED Highlights Savolitinib SAVANNAH Phase II and Other Data at European Lung Cancer Congress 2025
From HUTCHMED (China) Limited
Via GlobeNewswire
Hutchmed's Oncology Revenue Hits $271.5 Million, Rising 65% On Fruzaqla Strength
Via Benzinga
HUTCHMED Reports 2024 Full Year Results and Provides Business Updates
From HUTCHMED (China) Limited
Via GlobeNewswire
Earnings Scheduled For March 19, 2025
Via Benzinga
HUTCHMED and Innovent Jointly Announce that the FRUSICA-2 Phase II/III Study of Fruquintinib and Sintilimab Combination Has Met its Primary Endpoint in Advanced Renal Cell Carcinoma in China
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED Announces that it has Completed Enrollment of a Phase II Registration Study of Fanregratinib (HMPL-453) for Intrahepatic Cholangiocarcinoma in China
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED to Announce 2024 Final Results
From HUTCHMED (China) Limited
Via GlobeNewswire

Frequently Asked Questions

Is HUTCHMED (China) Limited - American Depositary Shares publicly traded?
Yes, HUTCHMED (China) Limited - American Depositary Shares is publicly traded.
What exchange does HUTCHMED (China) Limited - American Depositary Shares trade on?
HUTCHMED (China) Limited - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for HUTCHMED (China) Limited - American Depositary Shares?
The ticker symbol for HUTCHMED (China) Limited - American Depositary Shares is HCM on the Nasdaq Stock Market
What is the current price of HUTCHMED (China) Limited - American Depositary Shares?
The current price of HUTCHMED (China) Limited - American Depositary Shares is 16.21
When was HUTCHMED (China) Limited - American Depositary Shares last traded?
The last trade of HUTCHMED (China) Limited - American Depositary Shares was at 08/19/25 04:00 PM ET
What is the market capitalization of HUTCHMED (China) Limited - American Depositary Shares?
The market capitalization of HUTCHMED (China) Limited - American Depositary Shares is 14.12B
How many shares of HUTCHMED (China) Limited - American Depositary Shares are outstanding?
HUTCHMED (China) Limited - American Depositary Shares has 14B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.